Abstract
In moving from traditional endpoints to innovative outcomes in determining the benefits of medicines, five aspects should be considered, namely, the key issues to be addressed, the need for such a change direction, the benefits of the socioeconomic approach, the opportunities available in estimating benefits, and the principles to be considered and implemented.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ware JE, Brook RH, Davies-Avery A, Lohv KN (1981) Choosing measures of health studies for individuals and general population. Am J Public Health 71:620–625
Buxton MJ, Drummond MR (1990) Quality of life measurement in the development of medicines. Pharmaceut J 3 Mar:260–262
Read JL (1988) From medical to socioeconomic evaluation of drug therapy. In: van Eimeren W, Horisberger B (eds) Socioeconomic evaluation of drug therapy. Springer, Berlin Heidelberg New York Tokyo, pp 72–81
Spilker B (1990) Quality of life assessment in clinical trials. Raven, New York
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Walker, S.R. (1991). The Socioeconomic Evaluation of Medicines: A New Dimension. In: Dinkel, R., Horisberger, B., Tolo, K.W. (eds) Improving Drug Safety — A Joint Responsibility. Health Systems Research. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61250-3_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-61250-3_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64762-8
Online ISBN: 978-3-642-61250-3
eBook Packages: Springer Book Archive